These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 3927468

  • 41. Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Patients taking selegeline may have received more levodopa than necessary.
    Olanow CW, Godbold JH, Koller W.
    BMJ; 1996 Mar 16; 312(7032):702-3; author reply 704-5. PubMed ID: 8597746
    [No Abstract] [Full Text] [Related]

  • 42. Monoamine oxidase inhibitors and their pharmacological significance.
    Sandler M.
    Acta Neurol Scand Suppl; 1983 Mar 16; 95():37-41. PubMed ID: 6428147
    [Abstract] [Full Text] [Related]

  • 43. Protective effect of selegiline in the early and late phases of Parkinson's disease.
    Csanda E, Tárczy M.
    Adv Neurol; 1993 Mar 16; 60():672-5. PubMed ID: 8420208
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Effect of adding selegeline to levodopa in early, mild Parkinson's disease. "On treatment" rather than intention to treat analysis should have been used.
    Gerlach M, Riederer P, Vogt H.
    BMJ; 1996 Mar 16; 312(7032):704; author reply 704-5. PubMed ID: 8597750
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Parkinson's disease.
    Imke S.
    Adv Nurse Pract; 1998 Jan 16; 6(1):24-8. PubMed ID: 9495941
    [No Abstract] [Full Text] [Related]

  • 48. Selegiline in the treatment of Parkinson's disease.
    Heinonen EH, Rinne UK.
    Acta Neurol Scand Suppl; 1989 Jan 16; 126():103-11. PubMed ID: 2515715
    [Abstract] [Full Text] [Related]

  • 49. Elucidating the mechanism of action and potential interactions of MAO-B inhibitors.
    Bainbridge JL, Page RL, Ruscin JM.
    Neurol Clin; 2008 Aug 16; 26(3 Suppl):S85-96, vi. PubMed ID: 18774444
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. [A long-term clinical effect of selegiline hydrochloride on Parkinson's disease].
    Mizuno Y, Kondo T, Takubo H, Yokochi F.
    No To Shinkei; 1996 May 16; 48(5):467-72. PubMed ID: 8672306
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. MPTP: clinical implications.
    Stern G.
    J Neural Transm Suppl; 1986 May 16; 20():77-81. PubMed ID: 3091763
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.